Abstract B017: Novel mesothelin-based CAR T cells targeting MUC16 as an intravesical bladder cancer therapy
Authors: Parwiz Abrahimi, Jonathan Khan, Renier Brentjens, Taha Merghoub, Jedd Wolchok
Journal: Clinical Cancer Research (2024)

Abstract Intravesical therapies have been the mainstay of non-muscle invasive bladder cancer (BC) management; however, their efficacy is limited by toxicities, recurrences, and supply shortages. Consequently, many patients are recommended cystectomy, which is fraught with high complication rates. Thus, bladder-sparing treatments present a major, unmet clinical need. Chimeric antigen receptor (CAR) T cell therapy, wherein T cells are engineered to express an artificial receptor to a target, is an immunotherapeutic approach with efficacy in hematologic malignancies. Similar success in solid tumors has been hindered by a lack of suitable targets, reduced T cell infiltration/activity, and major toxicities, including on-target off-tumor effects and cytokine release syndromes. To overcome these limitations, locoregional delivery of CAR T cells is being investigated. Yet, to date, no studies have examined their potential as intravesical therapies. In this study, we used a computational pipeline using large-scale BC transcriptomics data to discover potential CAR targets which met strict criteria of high cell-surface expression on BC and minimal expression on normal tissue. We identified MUC16, a surface-bound mucinous glycoprotein, as a top candidate from this pipeline, which has more reduced pan-tissue expression than targets of precision-guided therapies in BC. Consistent with prior reports, MUC16 transcript and protein levels increase with grade and T stage and correlates with chemotherapeutic resistance. We also find MUC16 expression persists in recurrent tumors after BCG-therapy. To target MUC16, we designed second-generation CARs based on scFv derived from the antibody 3a5 (3a5-28z) and natural-ligands based on the high-affinity MUC16-mesothelin interaction (MSLN-28z) or its truncated binding domain (truncMSLN-28z) which were fused to CD28 co-stimulatory domains and CD3z chains of the T cell receptor. Using human BC lines with a broad range of MUC16 levels, we show MSLN-28z more effectively lyses MUC16+, but not MUC16−, cells than compared to 3a5-28z or truncMSLN-28z CAR T cells. Ablation of MUC16 by CRISPR/Cas9 or modification of MSLN-based CAR to lack signaling domains abolishes the cytotoxicity of MSLN-28z CAR T cells, demonstrating dependency on MUC16 engagement. Using multiplex assays and intracellular cytokine staining, we further demonstrate MSLN-28z CAR T cells have potent polyfunctionality through secretion of cytokines IL-2, IFN-g, and TNF-a by both CD4+ and CD8+ subsets. Last, in immunodeficient mice orthotopically xenografted with HT1376 cells, intravesical delivery of MSLN-28z CAR T cells enhances survival compared to CAR T cells delivered intravenously. This enhanced anti-tumor response correlates with reduced tumor weights and increased T cell infiltration. Notably, intravesically delivered CAR T cells are not detectable in peripheral circulation of tumor-bearing mice. Together, our findings substantiate MUC16 as a targetable antigen in BC and validate MSLN-based CAR T cells as a potential intravesical therapy. Citation Format: Parwiz Abrahimi, Jonathan Khan, Renier Brentjens, Taha Merghoub, Jedd Wolchok. Novel mesothelin-based CAR T cells targeting MUC16 as an intravesical bladder cancer therapy [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2024 May 17-20; Charlotte, NC. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(10_Suppl):Abstract nr B017.